ASCO said it will not recommend Grail’s Galleri multi-cancer early detection test for screening guidelines after reviewing new trial data. The coverage highlighted that the NHS-Galleri randomized study failed to meet its primary endpoint, a key evidentiary bar for reducing the incidence of multiple late-stage cancers. ASCO’s decision adds another institutional checkpoint in the MCED debate, even as discussion remains around secondary signals such as stage IV reduction and earlier detection patterns.